Upgrade a Arbutus Biopharma

75
Le han subido el rating a Outperform.
Las cifras de consenso para los ingresos y las ganancias por acción (EPS) aumentaron, con perspectivas optimistas

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.